Secukinumab (AIN457) in the treatment of ankylosing spondylitis

References

• Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005;52:1000–1008. doi:10.1002/art.20990.
   PubMed Web of Science ®Google Scholar
• Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127–2137. doi:10.1016/S0140-6736(11)60071-8.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64(6):905–910. doi:10.1002/acr.21621.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11:229. doi:10.1186/ar2684.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis. 2010;69(8):1465–1470. doi:10.1136/ard.2009.124206.
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–1390. doi:10.1016/S0140-6736(07)60635-7.
   PubMed Web of Science ®Google Scholar
• Kiltz U, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis. 2015;74(5):830–835. doi:10.1136/annrheumdis-2013-203967.
   PubMed Web of Science ®Google Scholar
• Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2015 Oct 21. doi:10.1136/annrheumdis-2015-eular.2064. [Epub ahead of print].
   Web of Science ®Google Scholar
• Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4–11.
   PubMedGoogle Scholar
• Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007;57:639–647. doi:10.1002/art.22669.
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–368.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (pat II): validation and final selection. Ann Rheum Dis. 2009;68:777–783. doi:10.1136/ard.2009.108233.
   PubMed Web of Science ®Google Scholar
• Braun J, Van Den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896–904. doi:10.1136/ard.2011.151027.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:905–908. doi:10.1136/ard.2011.151563.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187–1193.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–2146. doi:10.1002/art.21913.
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230–3236. doi:10.1002/art.11325.
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC Jr, Van Der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, Phase III trial. Arthritis Rheum. 2008;58:3402–3412. doi:10.1002/art.23969.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582–591. doi:10.1002/art.20852.
   PubMed Web of Science ®Google Scholar
• Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39–47. doi:10.1136/annrheumdis-2013-204231.
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Akl EA, et al. American college of rheumatology/spondylitis association of america/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282–298. doi:10.1002/art.39298.
   Web of Science ®Google Scholar
• Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16. doi:10.1136/annrheumdis-2013-203419.
   PubMed Web of Science ®Google Scholar
• O’Connor W Jr, Zenewicz LA, Flavell RA. The dual nature of T(H)17 cells: shifting the focus to function. Nat Immunol. 2010;11:471–476. doi:10.1038/ni.1882.
   PubMed Web of Science ®Google Scholar
• Braun J, Kiltz U, Heldmann F, et al. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs. 2015;20(1):1–14. doi:10.1517/14728214.2015.993378.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326–328. doi:10.1056/NEJMoa1314258.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi:10.1016/j.jaad.2015.05.013.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2015;386(9999):1137–1146. doi:10.1016/S0140-6736(15)61134-5.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339. doi:10.1056/NEJMoa1412679.
   PubMed Web of Science ®Google Scholar
• Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71(5):661–667. doi:10.1136/ard.2011.154799.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years–early clinical response predicts long-term outcome. Rheumatology (Oxford). 2011;50:1690–1699. doi:10.1093/rheumatology/ker194.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439–R444. doi:10.1186/ar1693.
   Google Scholar
• van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324–1331. doi:10.1002/art.23471.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014;73(6):1107–1113. doi:10.1136/annrheumdis-2012-203075.
   PubMed Web of Science ®Google Scholar
• Coates LC, Marzo-Ortego H, Bennett AN, et al. Anti-TNF therapy in ankylosing spondylitis: insights for the clinician. Ther Adv Musculoskelet Dis. 2010;2:37–43. doi:10.1177/1759720X09359728.
   PubMedGoogle Scholar
• Braun J, Kudrin A. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy. 2015;7(2):73–87. doi:10.2217/imt.14.109.
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74:1051–1057. doi:10.1136/annrheumdis-2013-204963.
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:95–100. doi:10.1136/annrheumdis-2013-203559.
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70:1108–1110. doi:10.1136/ard.2010.145946.
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64:296–298. doi:10.1136/ard.2004.023176.
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naïve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62:1290–1297. doi:10.1002/art.27383.
   PubMed Web of Science ®Google Scholar
• Pathan E, Abraham S, Van-Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72:1475–1480. doi:10.1136/annrheumdis-2012-201915.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. Press Release. Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis. 2014 Jul 9. [cited 2015 Jun 1]. Available from: http://ir.celgene.com/releasedetail.cfm?releaseid=858785
   Google Scholar
• Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817–823. doi:10.1136/annrheumdis-2013-204248.
   PubMed Web of Science ®Google Scholar
• Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012;122:487–511. doi:10.1042/CS20110496.
   PubMed Web of Science ®Google Scholar
• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763–776. doi:10.1038/nrd3794.
   PubMed Web of Science ®Google Scholar
• Martin DA, Towne JE, Kricorian G, et al. The emerging role of interleukin-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17–26. doi:10.1038/jid.2012.194.
   PubMed Web of Science ®Google Scholar
• Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72:ii116–ii123. doi:10.1136/annrheumdis-2012-202371.
   Google Scholar
• DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633–2643. doi:10.1002/art.24763.
   PubMed Web of Science ®Google Scholar
• Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012;64:110–120. doi:10.1002/art.33321.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069–1076. doi:10.1038/nm.2817.
   PubMed Web of Science ®Google Scholar
• Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol. 2014;26:361–370. doi:10.1097/BOR.0000000000000069.
   PubMed Web of Science ®Google Scholar
• Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60:1647–1656. doi:10.1002/art.24568.
   PubMed Web of Science ®Google Scholar
• Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186:2672–2680. doi:10.4049/jimmunol.1002653.
   PubMed Web of Science ®Google Scholar
• Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64:1420–1429. doi:10.1002/art.33507.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Wu P, et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13:R95. doi:10.1186/ar3370.
   PubMed Web of Science ®Google Scholar
• Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64:99–109. doi:10.1002/art.33396.
   PubMed Web of Science ®Google Scholar
• Zambrano-Zaragoza JF, Agraz-Cibrian JM, González-Reyes C, et al. Ankylosing spondylitis: from cells to genes. Int J Inflam. 2013;2013:501653. doi:10.1155/2013/501653.
   PubMedGoogle Scholar
• Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45:730–738. doi:10.1038/ng.2667.
   PubMed Web of Science ®Google Scholar
• Kondo M, Yamaoka K, Sonomoto K, et al. IL-17 inhibits chondrogenic differentiation of human mesenchymal stem cells. PloS One. 2013;8:e79463.
   PubMed Web of Science ®Google Scholar
• Sylvester J, Liacini A, Li WQ, et al. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, −13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal. 2004;16(4):469–476.
   PubMed Web of Science ®Google Scholar
• Van Hamburg JP, Asmawidjaja PS, Davelaar N, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum. 2011;63(1):73–83.
   PubMed Web of Science ®Google Scholar
• Starodubtseva NL, Sobolev VV, Soboleva AG, et al. Expression of genes for metalloproteinases (MMP-1, MMP-2, MMP-9, and MMP-12) associated with psoriasis. Genetika. 2011;47(9):1254–1261.
   PubMedGoogle Scholar
• Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015;27(2):127–133. doi:10.1097/BOR.0000000000000147.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–1141. doi:10.1053/j.gastro.2008.07.014.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–1528. doi:10.1056/NEJMoa1203572.
   PubMed Web of Science ®Google Scholar
• Maddur MS, Vani J, Hegde P, et al. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol. 2011;127(3):823–830.e1–e7. doi:10.1016/j.jaci.2010.12.1102.
   PubMed Web of Science ®Google Scholar
• Maddur MS, Kaveri SV, Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev. 2011;10(12):809–810. doi:10.1016/j.autrev.2011.02.007.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Mutebi A, et al. Improvement in psoriasis signs and symptoms assessed by the psoriasis symptom inventory with brodalumab treatment in patients with psoriatic arthritis. J Rheumatol. 2016;43(2):343–349. doi:10.3899/jrheum.150182.
   PubMed Web of Science ®Google Scholar
• Kopf H, De La Rosa GM, Howard OM, et al. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol. 2007;7(13):1819–1824. doi:10.1016/j.intimp.2007.08.027.
   PubMed Web of Science ®Google Scholar
• EMA Public Assessment Report. Cosentyx (secukinumab) EMA/CHMP/389874/2014. 2014 Nov 20. [cited 2015 Jun 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003729/WC500183131.pdf
   Google Scholar
• Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490–500. doi:10.4049/jimmunol.1100123.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509. doi:10.1056/NEJMra0804595.
   PubMed Web of Science ®Google Scholar
• Res PC, Piskin G, De Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 2010;5:e14108. doi:10.1371/journal.pone.0014108.
   PubMed Web of Science ®Google Scholar
• Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity. 2011;35:596–610. doi:10.1016/j.immuni.2011.08.001.
   PubMed Web of Science ®Google Scholar
• Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888–898. doi:10.1056/NEJMra0707449.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi:10.1126/scitranslmed.3001107.
   PubMed Web of Science ®Google Scholar
• Bayry J, Sibéril S, Triebel F, et al. Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today. 2007;12:548–552. doi:10.1016/j.drudis.2007.05.002.
   PubMed Web of Science ®Google Scholar
• Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75:329–338. doi:10.1007/s40265-015-0359-0.
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Kramer JM, Yu JJ, et al. The IL-17 cytokine family. Vitam Horm. 2006;74:255–282. doi:10.1016/S0083-6729(06)74010-9.
   PubMed Web of Science ®Google Scholar
• Cosentyx SmPC. Available from: http://www.medicines.org.uk/emc/medicine/29848
   Google Scholar
• Baeten D, Sieper J, Emery P, et al. The anti-IL17a monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Ann Rheum Dis. 2011;70(Suppl3):127. doi:10.1136/ard.2010.139832.
   Web of Science ®Google Scholar
• Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos. 2001;29:207–212.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody Secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–1713. doi:10.1016/S0140-6736(13)61134-4.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75(2):408–412. doi:10.1136/annrheumdis-2015-207544.
   Web of Science ®Google Scholar
• Baeten D, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week Phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Oral presentation at: ACR/ARHP Annual Meeting; Boston, MA, USA; 2014. Arthritis Rheum 2014;66(Suppl):S360. Abstract 819
   Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–2548. doi:10.1056/NEJMoa1505066.
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a Phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Poster presentation at: ACR/ARHP Annual Meeting; Boston, MA, USA; 2014. Arthritis Rheum 2014;66(Suppl):S232.Abstract 536
   Google Scholar
• Baraliakos X, Deodhar A, Braun J, et al. Effect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab. Late breaking abstract presented at: ACR/ARHP Annual Meeting; San Francisco, USA; 2015 Nov 10. Arthritis Rheumatol. 2015; 67 (suppl 10): Late Breaking Abstract 6L
   Google Scholar
• Baraliakos X, Braun J, Sieper J, et al. Secukinumab reduces sacroiliac joint and spinal inflammation in patients with ankylosing spondylitis: MRI data from a phase 3 randomized, double-blind, placebo-controlled study (MEASURE 1). Poster presentation at: European League Against Rheumatism (EULAR); Rome, Italy; 2015 Sep 11. Ann Rheum Dis 2015;74(Suppl2):281 doi:10.1136/annrheumdis-2015-eular.3008.
   Google Scholar
• Baeten D, Braun J, Sieper J, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2-year efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled trial. Presented at: ACR/ARHP Annual Meeting; San Francisco, USA; 2015 Nov 10. Arthritis Rheumatol. 2015; 67 (suppl 10): Abstract 2896
   Google Scholar
• Ogdie A, Yu YD, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–332.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700.
   PubMed Web of Science ®Google Scholar
• Wendling D, Joshi A, Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515–2521.
   PubMed Web of Science ®Google Scholar
• Summary basis of approval for FDA [cited 2015 Jul]: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM419023
   Google Scholar
• Blauvellt A, Szepietowski J, Sigurgeirsson B, et al. Secukinumab treatment maintains efficacy in moderate-to-severe plaque psoriasis through second year of treatment: a randomized extension of the ERASURE and FIXTURE studies [Internet]. Presented at: 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco. [cited 2015 Mar 24]. Available from: https://www.aad.org/Symposium/LBAM2015/file/index/Late-breaking%20Research%20Abstract%20Book.pdf
   Google Scholar